Related Experiment Video
Updated: Jul 14, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and
Xiaopeng Wang1,2,3, Li Kong1,2,3, Xueou Liu4
1Department of Neonatology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China.
Insights
Nirsevimab significantly reduces respiratory syncytial virus (RSV) infections in preterm infants. This monoclonal antibody offers a valuable new preventive measure for this vulnerable population.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory Syncytial Virus (RSV) causes severe respiratory infections in preterm infants.
- Nirsevimab is a novel monoclonal antibody showing promise for RSV prevention.
- A comprehensive evaluation of nirsevimab's efficacy in preterm infants is needed.
Purpose of the Study:
- To systematically review and meta-analyze the effectiveness of nirsevimab in preventing RSV-related lower respiratory tract infections in preterm infants.
Main Methods:
- A systematic search of PubMed and EMBASE identified relevant randomized controlled trials and observational studies.
- Data from included studies were extracted and subjected to meta-analysis.
- Five studies with 7,347 preterm infants were analyzed.
Main Results:
- Nirsevimab significantly reduced medically attended RSV-associated lower respiratory tract infections (OR = 0.25).
- Nirsevimab significantly decreased hospitalizations due to RSV-associated lower respiratory tract infections (OR = 0.27).
- The findings were statistically significant (P < 0.0001 for both outcomes).
Conclusions:
- Nirsevimab is an effective intervention for preventing RSV-related infections in preterm infants.
- This monoclonal antibody represents a valuable tool for protecting vulnerable infants from RSV.
Background:
Respiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society. Nirsevimab, a recently developed RSV monoclonal antibody, has demonstrated promising efficacy in this population according to preliminary studies. However, there remains a need for comprehensive systematic reviews and meta-analyses to evaluate the effectiveness of nirsevimab in preventing RSV-related lower respiratory tract infections in preterm infants.
Methods:
A search of the PubMed and EMBASE databases was conducted to identify randomized controlled trials (RCTs) and observational studies assessing the prevention of RSV infection in preterm infants using nirsevimab. Relevant data were extracted and subjected to meta-analysis.
Results:
Five studies involving a total of 7,347 preterm infants (3,987 in the nirsevimab group and 3,360 in the control group) were included. The meta-analysis revealed that nirsevimab significantly reduced the incidence of medically attended RSV-associated lower respiratory tract infections (OR = 0.25; 95% CI: 0.15, 0.40; P < 0.0001) and hospitalizations due to RSV-associated lower respiratory tract infections (OR = 0.27; 95% CI: 0.19, 0.38; P < 0.0001).
Conclusion:
Nirsevimab significantly decreases the risk of RSV-related infection in preterm infants and represents a valuable intervention for RSV prevention in this vulnerable population.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD42025629937.
